Thermo Fisher Scientific Inc. has announced the acquisition of Sanofi's sterile manufacturing site in Ridgefield, New Jersey, as part of an expanded strategic partnership aimed at bolstering U.S. drug product manufacturing capacity. The transaction, expected to close in the second half of 2025, will enable Thermo Fisher to continue manufacturing Sanofi's therapeutic portfolio while expanding services to meet growing demand from pharmaceutical and biotech customers.
Strategic Manufacturing Expansion
The Ridgefield facility represents a significant addition to Thermo Fisher's manufacturing capabilities, featuring state-of-the-art sterile fill-finish and packaging operations. The site employs more than 200 professionals who will join Thermo Fisher following transaction completion, bringing specialized expertise in sterile drug manufacturing.
"Sanofi's Ridgefield site will strengthen our U.S. manufacturing capabilities, enabling us to better support our pharmaceutical and biotech customers with the critical production capacity needed for essential medicines," said Marc N. Casper, chairman, president and CEO of Thermo Fisher. "We will also expand and further strengthen our long-standing partnership with Sanofi, while investing to bring additional capacity and enhanced capabilities at this site."
Continued Partnership Benefits
Under the agreement, Thermo Fisher will maintain production of Sanofi's existing therapeutic portfolio at the Ridgefield facility, ensuring continuity of supply for patients and healthcare providers. The arrangement reflects both companies' commitment to maintaining robust U.S. manufacturing capabilities for critical medicines.
Brendan O'Callaghan, global head of manufacturing & supply at Sanofi, emphasized the partnership's strategic value: "This expansion of our long-term partnership with Thermo Fisher will help ensure a continued supply of high-quality Sanofi products, maintaining our commitment to American manufacturing and supporting our customers and patients in the U.S., while enabling the future development and growth of the site."
Enhanced Manufacturing Network
The acquisition will integrate the Ridgefield facility into Thermo Fisher's existing sterile fill-finish manufacturing network, which currently includes U.S. sites in Greenville, North Carolina and Plainville, Massachusetts. These facilities are integral components of the company's Accelerator™ Drug Development 360° CDMO and CRO solutions, designed to accelerate pharmaceutical development for emerging biotech and biopharma companies.
Upon completion, the Ridgefield facility will become part of Thermo Fisher's pharma services business within its Laboratory Products and Biopharma Services segment. The company, which generates annual revenue exceeding $40 billion, positions itself as a world leader in serving science through its comprehensive portfolio of innovative technologies and pharmaceutical services.
Transaction Details
The transaction remains subject to customary closing conditions, with completion anticipated in the second half of 2025. Financial terms of the deal were not disclosed by either company. The acquisition represents Thermo Fisher's continued investment in expanding manufacturing capacity to serve the growing needs of the pharmaceutical and biotechnology sectors in the United States.
